PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
22-Aug-2024 In Pursuit of Excellence: State of the Art Electronic Consent for Clinical Trials Newswire
22-Aug-2024 Neurocare Group Receives FDA Clearance for Its Industry-Leading Intermittent Theta Burst Stimulation (iTBS) Protocol for Transcranial Magnetic Stimulation (TMS) AccessWire
22-Aug-2024 MRES: M2Bio Food and Beverage Refocuses Strategy: Expanding Beyond CBD to Reach Global Consumers AccessWire
22-Aug-2024 Stemtech Expands Into The $303 Billion Pet Health Care Market With Launch Of Stempets(TM) AccessWire
22-Aug-2024 Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study AccessWire
22-Aug-2024 CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment AccessWire
22-Aug-2024 KindlyMD(TM) Appoints Nancy Pratt as Behavioral Health Program Director AccessWire
22-Aug-2024 Aspen Dental: What to Expect During These 5 Common Dental Procedures in Allentown AccessWire
22-Aug-2024 DATA SUPPORTING FDA APPROVAL PUBLISHED IN HIGH-IMPACT JOURNAL ANGLE plc
22-Aug-2024 PureTech Appoints Michele Holcomb, PhD, to Board of Directors PureTech Health plc
22-Aug-2024 Unaudited Interim Results for the six months ended 30 June 2024 Cambridge Cognition Holdings plc
22-Aug-2024 Xcelerate, Inc. Announces Commencement of the Nationalization Process for its PCT International Patent Applications AccessWire
22-Aug-2024 Coulter Partners places industry veteran Dr. David Hung as Chair of T-Therapeutics Coulter Partners
22-Aug-2024 Moderna to Host Investor Event - R&D Day and Business Updates AccessWire
22-Aug-2024 Arrival of deadlier ‘clade I’ mpox in Europe highlights need for better testing and treatment: expert London Medical Laboratory
22-Aug-2024 Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus Touchlight
22-Aug-2024 GermFree and Caring Cross partner to transform access to cellular gene therapies GermFree
22-Aug-2024 Hevolution Foundation and Dolby Family Ventures join Vandria’s 2nd Series A closing, bringing the total round to $30.7M (CHF 28.3M) to Progress the Mitophagy Inducer VNA-318 into CNS Clinical Development Vandria SA
22-Aug-2024 Breaking down barriers DeSci Labs
22-Aug-2024 Kelso Pharma appoints first Director of Corporate Development as international expansion continues Kelso Pharma